ClinicalTrials.gg
RecruitingNCT07141706Updated Jul 27, 2026

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

A Phase 1 interventional study of DB-1317 in Advanced/Metastatic Solid Tumors, sponsored by DualityBio Inc.. Recruiting at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by DualityBio Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
253
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes one randomized dose expansion cohort and two single-arm dose expansion cohorts to further evaluate the safety, tolerability and preliminary efficacy of DB-1317 in selected solid tumors and to identify optimal RP2D.

Read the detailed description

Phase 1a (Dose Escalation and Backfilling)

Approximately 5 increasing dose levels of DB-1317 dosing every 3 weeks (Q3W) will be evaluated using an accelerated titration design at the first dose level, followed by a BOIN design at subsequent dose levels with the oversight of a Safety Monitoring Committee (SMC). For safety reasons, in any dose level of the dose escalation where a number of participants ≥ 2, a staggered dosing is required. The second participant in each dose level should start dosing no sooner than at least 24 hours after the initial dosing of the first participant. If no safety concerns arise during these 24 hours, the remaining participants can be enrolled into the same dose level with no additional staggering required. Each dose level will be subject to the DLT assessment. After completing the 21-day DLT observation period (Cycle 1), participants will continue to the next treatment cycle and receive DB-1317 on Day 1 of each cycle in the same dose level cohort. Participants who complete the DLT observation period are not allowed to switch to a higher dose level (i.e., intra-participant escalation is not allowed) unless it is deemed necessary and strongly recommended by the investigator with a written approval by the Sponsor.

Upon confirmation of MTD or MAD of DB-1317 based on data from the completed dose-escalation phase, the safety dose range of DB-1317 may be defined based on cumulative data. Following confirmation by the SMC, alternative dosing regimens, such as Q2W may be explored within the established safety dose range.

Phase 1b (Dose Expansion)

Upon completion of the Phase 1a dose escalation, following determination of MTD or MAD, and at the Sponsor's discretion, -one randomized expansion cohort and two single arm expansion cohorts will be opened each enrolling one of the selected solid tumor types, if preliminary anti-tumor activities in these tumor types are observed in Phase 1a part. GC is the tumor type pre-selected for the randomized expansion cohort CRC and PDAC are the two tumor types pre-selected for the single arm expansion cohorts based on ADAM9 expressing data, in vivo anti-tumor activities in non-clinical tumor models, and consideration of unmet medical needs. The final selection of tumor type(s) to be enrolled in the Phase 1b cohorts will be determined by Sponsor based on emerging data from Phase 1a part. Approximately 80 participants will be enrolled in the randomized expansion cohort and randomly assigned in a 1:1 ratio to two dose levels (approximately 40 each) . Approximately 40 participants will be enrolled in each single arm expansion cohort at a selected dose level, and 160 participants will be enrolled in Phase 1b. Dose levels used in Phase 1b part will be determined by Sponsor and SMC based on Phase 1a data. Based on new emerging data from the study, Sponsor may explore other randomized cohorts with other tumor types.

02

Conditions studied

  • Advanced/Metastatic Solid Tumors

Keywords

  • ADAM9
  • Solid tumor
  • DB-1317
03

In context

Lead sponsor

DualityBio Inc. is the lead sponsor of 12 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female adults
  2. Unresectable advanced or selected solid tumors that have or progressed on or after standard systemic treatments.
  3. Only applicable to backfilling participants in Phase 1a and participants in Phase 1b: At least one as assessed by the investigator according to version 1.1 criteria. Participants with non-measurable disease are allowed for CRPC participants.
  4. Has a of ≥ 3 months.
  5. Has an PS of 0-1.
  6. Has ≥ 50% within 28 days before enrollment.
  7. Is willing to provide pre-existing resected tumor samples or undergo fresh tumor for the measurement of ADAM9 expression level and other biomarkers if no .
  8. Male and female participants of reproductive/ must agree to use adequate methods

Key Exclusion Criteria:

  1. Prior treatment with ADAM9 targeted therapy.
  2. Prior treatment with antibody-drug conjugate with topoisomerase I inhibitor.
  3. Has a medical history of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment.
  4. Has a medical history of myocardial infarction or unstable angina within 6 months before enrollment.
  5. Has any abnormalities in rhythm, conduction or morphology of resting
  6. Has an average of Fredericia's formula- corrected interval (QTcF) prolongation to > 470 ms in males and females
  7. Has a history of (non-infectious) ILD/pneumonitis
  8. Has a lung-specific intercurrent clinically significant illness
  9. Has an uncontrolled infection requiring intravenous injection of antibiotics, antivirals, or antifungals.
  10. Known (HIV) infection;Chronic, active, or uncontrolled ;
  11. Known chronic, active, or uncontrolled
  12. Has clinically significant corneal disease.
  13. Has clinically active
  14. Has unresolved toxicities from previous anticancer therapy Concurrent \< 3 years.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
253 participants (estimated)

Study arms

  • Experimental
    DB-1317 Dose Level 1

    Enrolled Subjects will receive a single-dose of DB-1317 at Dose Level 1 on Day 1 of each cycle Q3W

    Drug: DB-1317

  • Experimental
    DB-1317 Dose Level 2

    Enrolled Subjects will receive a single-dose of DB-1317 at Dose Level 2 on Day 1 of each cycle Q3W

    Drug: DB-1317

  • Experimental
    DB-1317 Dose Level 3

    Enrolled Subjects will receive a single-dose of DB-1317 at Dose Level 3 on Day 1 of each cycle Q3W

    Drug: DB-1317

  • Experimental
    DB-1317 Dose Level 4

    Enrolled Subjects will receive a single-dose of DB-1317 at Dose Level 4 on Day 1 of each cycle Q3W

    Drug: DB-1317

  • Experimental
    DB-1317 Dose Level 5

    Enrolled Subjects will receive a single-dose of DB-1317 at Dose Level 5 on Day 1 of each cycle Q3W

    Drug: DB-1317

  • Experimental
    DB-1317 Dose Expansion 1

    Subjects with advanced/unresectable, or metastatic Gastric cancer (GC) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1317

    Drug: DB-1317

  • Experimental
    DB-1317 Dose Expansion 2

    Subjects with advanced/unresectable, or metastatic colorectal cancer (CRC) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1317

    Drug: DB-1317

  • Experimental
    DB-1317 Dose Expansion 3

    Subjects with advanced/unresectable, or metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1317

    Drug: DB-1317

  • Experimental
    DB-1317 Dose Level 6

    Enrolled Subjects will receive a single-dose of DB-1317 at Dose Level 6 on Day 1 of each cycle Q2W

    Drug: DB-1317

Interventions

  • DrugDB-1317

    Administered I.V.

06

What researchers measure

Primary outcomes

  1. Phase 1a: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE v5.0. Percentage of participants in Part 1 with DLTs

    Percentage of participants in Phase 1a with DLTs

    Time frame: up to 21 days after Cycle 1 Day 1

  2. Phase 1a: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0.

    Percentage of participants with TEAEs in Phase 1a graded according to NCI CTCAE v5.0

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  3. Phase 1a: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.

    Percentage of Participants with SAEs in Phase 1a graded according to NCI CTCAE v5.0

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  4. Maximum Tolerated Dose (MTD) of DB-1317

    MTD on the data collected during Phase 1a

    Time frame: Up to the completion of Phase 1a (assessed up to 12 months)

  5. Recommended Phase 1b Dose (RP2D) of DB-1317

    RP2D of DB-1317 based on the data collected during Phase 1a

    Time frame: Up to the completion of Phase 1a (assessed up to 12 months)

  6. Phase 1b: Percentage of Participants with Treatment Emergent adverse events (TEAEs) as assessed by CTCAE v5.0.

    Percentage of participants with TEAEs in Phase 1b graded according to NCI CTCAE v5.0

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  7. Phase 1b: Percentage of participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.

    Percentage of participants with SAEs in Phase 1b graded according to NCI CTCAE v5.0

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  8. Phase 1b: Objective Response Rate (ORR) as determined by investigator

    Phase 1b: Objective Response Rate (ORR) as determined by investigator per RECIST 1.1 in non-CRPC. The percentage of participants who had a best response rating of CR and PR, for Part 2 only which was maintained ≥4 weeks

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  9. Phase 1b: duration of response (DoR)

    DoR will be determined from tumor assessments by investigator per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  10. Phase 1b: disease-control rate (DCR)

    DCR will be determined from tumor assessments by investigator per response

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  11. Phase 1b: Time to Response (TTR)

    TTR will be determined from tumor assessments by investigator per response

    Time frame: Up to follow-up period, approximately 1 year post-treatment

Secondary outcomes

  1. Phase 1a: Objective response rate (ORR)

    ORR will be determined from tumor assessments by investigator per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  2. Phase 1a: duration of response (DoR)

    DoR will be determined from tumor assessments by investigator per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  3. Phase 1a: disease-control rate (DCR)

    DCR will be determined from tumor assessments by investigator per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  4. Phase 1a: Time to Response (TTR)

    TTR will be determined from tumor assessments by investigator per response evaluation TTR criteria in solid tumors version 1.1 (RECIST v1.1)

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  5. Phase 1a & Phase 1b: Progression Free Survival (PFS)

    PFS will be determined from tumor assessments by investigator per response evaluation PFS criteria in solid tumors version 1.1 (RECIST v1.1)

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  6. Phase 1a & Phase 1b: Overall Survival (OS)

    OS is defined as the time from date of first dose to the date of death.

    Time frame: From date of first dose until the date of death or lost to follow up, approximately 1 year post-treatment

  7. Phase 1a: Prostate-specific antigen (PSA)

    Time to PSA progression, PSA50 response rate and PSA90 response rate, duration of PSA response in CRPC subjects.

    Time frame: From date of first dose until the date of first PSA progression, approximately 1 year post-treatment

  8. Phase 1a & Phase 1b: Pharmacokinetic-AUC

    Area under the concentration-time curve from time 0 to infinity of DB-1317 ADC, total anti-Adam 9 antibody, and unconjugated P1003

    Time frame: within 3 cycles (each cycle is 21 days)

  9. Phase 1a & Phase 1b: Pharmacokinetic-Cmax

    Maximum observed plasma concentration (Cmax) of DB-1317 ADC, total anti-Adam 9 antibody, and unconjugated P1003

    Time frame: within 3 cycles (each cycle is 21 days)

  10. Phase 1a & Phase 1b: Pharmacokinetic-Tmax

    Time to Cmax of DB-1317 ADC, total anti-Adam 9 antibody, and unconjugated P1003

    Time frame: within 3 cycles (each cycle is 21 days)

  11. Phase 1a & Phase 1b: Pharmacokinetic-Cthrough

    Trough concentration

    Time frame: within 6 cycles (each cycle is 21 days)

  12. Phase 1a & Phase 1b: Anti-drug antibody (ADA) prevalence

    Percentage of participants who are ADA positive at any point

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  13. Phase 1a & Phase 1b: ADA incidence

    Percentage of participants having treatment-emergent ADA

    Time frame: Up to follow-up period, approximately 1 year post-treatment

07

Study locations

14 of 14 sites recruiting
  • USA04-0
    Los Angeles, California 90025, United States
    Recruiting
  • USA05-0
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Site USA06-0
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
  • USA02-0
    Houston, Texas 77030, United States
    Recruiting
  • USA03-0
    San Antonio, Texas 78229, United States
    Recruiting
  • USA01-0
    Fairfax, Virginia 22031, United States
    Recruiting
  • AUS03-0
    Liverpool, New South Wales 2170, Australia
    Recruiting
  • AUS01-0
    Randwick, New South Wales 2031, Australia
    Recruiting
  • AUS04-0
    Westmead, New South Wales 2145, Australia
    Recruiting
  • AUS02-0
    Nedlands, Western Australia 6009, Australia
    Recruiting
  • Chn01-1/Chn01-2
    Guangzhou, Guangdong 510060, China
    Recruiting
  • CHN05-0
    Harbin, Heilongjiang, China
    Recruiting
  • CHN03-0
    Zhengzhou, Henan, China
    Recruiting
  • CHN04-0
    Jinan, Shandong, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jun 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2025
First posted
Aug 26, 2025
StartActual
Sep 23, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07141706
Lead sponsor
DualityBio Inc.
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Sep 23, 2025
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jul 27, 2026

Study contacts

Junhua Gao
Contact
junhua.gao@dualitybiologics.com
01067228087
Lily Hu
study director · DualityBio Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion